HIPRA is a biotech

pharmaceutical Medication (also called medicament, medicine, pharmaceutical drug, medicinal product, medicinal drug or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy ( pharmacotherapy) is an important part of the ...

company headquartered in Amer,

Catalonia Catalonia is an autonomous community of Spain, designated as a ''nationalities and regions of Spain, nationality'' by its Statute of Autonomy of Catalonia of 2006, Statute of Autonomy. Most of its territory (except the Val d'Aran) is situate ...

, Spain focused on prevention for animal and human health, with a product base of vaccines and diagnostic services. HIPRA has an international presence in 40 countries with its own subsidiaries, 3 R&D centres and production plants located in Europe (Spain) and America (Brazil). In addition, its international distribution network maintains open distribution channels with more than 100 countries, covering all 5 continents. Since 2020, the company has been developing a vaccine against

COVID-19 Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic. The symptoms of COVID‑19 can vary but often include fever ...

History

HIPRA got founded in 1971, in a small laboratory in Madrid. The name HIPRA comes from the surnames of its former creators: Hidalgo and Prada. In 1991 HIPRA had a workforce of 100 people and a turnover of 10 million euros, it was an important year in HIPRA's history, with a new management team, and a redefined company expansion policy.https://www.hipra.com/en/history Retrieved 2024-01-08 In the year 2000, the company began internationalization, beginning the implementation of its own subsidiaries around the world. Currently HIPRA has commercial subsidiaries in 40 countries. It also has 3 research centers and 6 production plants located in Europe and America. In 2009 HIPRA began to focus on prevention; therefore, it stopped investing in pharmacological products. In 2021 the new Human Health division was created by HIPRA to create new products. The same year, GoodGut was acquired by HIPRA, a biotechnological start-up dedicated to the research and development of diagnostic tests for digestive diseases. In the wake of the Covid-19 pandemic, HIPRA decided to branch out from its traditional veterinary medicine market to develop the country's first Covid-19 vaccine. The vaccine developed by HIPRA is an adjuvanted recombinant protein vaccine based on a receptor-binding domain (RBD) fusion heterodimer containing the alpha and beta variants of SARS-CoV-2. In June 2022, the Generalitat of Catalonia awarded HIPRA the Creu de Sant Jordi for "its involvement in the research of a new vaccine against the disease caused by the SARS-CoV-2 virus" and for its "commitment to the country's public health."

Animal health

HIPRA has developed more than 100 vaccines for different animal species, both production and companion animals, against a wide variety of biological targets. In addition to its Amer plant, the company has another plant in Brazil, in the Porto Alegre conurbation. It also has a university research centre in the United States. HIPRA's animal health products include vaccines, vaccination devices, integrated traceability services and diagnostic kits.

External links

hipra.com
, company website

References

Biotechnology companies of Spain Pharmaceutical companies of Spain Vaccination-related organizations {{Spain-company-stub